Cocrystal Pharma

COCP · NASDAQ

$0.9429−$0.0037 (−0.39%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.9466

COCP analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Dec 8, 2025

Bull case

Cocrystal Pharma Inc has demonstrated strong clinical progress with its investigational drug CDI-988, which has shown positive results from both multiple ascending dose (MAD) and single ascending dose (SAD) studies, reinforcing its potential as an effective antiviral treatment. The drug's ability to bind to the highly conserved region of the GII.17 protease, coupled with its effectiveness against emergent norovirus variants, highlights the robustness of its development strategy. Overall, these promising data points suggest that Cocrystal's commitment to innovative and targeted antiviral therapies could pave the way for significant advancements in the market.

Bear case

Cocrystal Pharma faces significant challenges that contribute to a negative outlook, primarily related to its lead candidate CC-31244. Key risks include the inability to identify a commercial partner and the potential failure to advance CC-31244 through clinical testing, coupled with difficulties in integrating this candidate into existing treatment regimens for hepatitis C. Additionally, setbacks with earlier-stage antiviral candidates, alongside potential near-term dilution risks, further exacerbate concerns about the company's future financial stability and growth trajectory.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.